← back to search

Jon Blatchford

King's College Hospital NHS Foundation Trust · DE
Area of research
Endocrinology, Diabetes and Metabolism · Cardiology and Cardiovascular Medicine
Research interest
Research interests include Diabetes Treatment and Management, Heart Failure Treatment and Management, Pancreatic function and diabetes, and Hyperglycemia and glycemic control in critically ill and hospitalized patients.
h-index
15
citations
3,304
works
26
NIH funding
primary concept
Medicine
email

Recent publications

Treatment Effects of Empagliflozin in Hospitalized Heart Failure Patients Across the Range of Left Ventricular Ejection Fraction – Results from the EMPULSE Trial
European Journal of Heart Failure 2024cited by 22position: middledoi
The Win Ratio Method in Heart Failure Trials: Lessons Learnt from EMPULSE
European Journal of Heart Failure 2023cited by 37position: middledoi
The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial
Nature Medicine 2022cited by 869position: middledoi
Impact of empagliflozin on decongestion in acute heart failure: the EMPULSE trial
European Heart Journal 2022cited by 207position: middledoi
Effects of Empagliflozin on Symptoms, Physical Limitations, and Quality of Life in Patients Hospitalized for Acute Heart Failure: Results From the EMPULSE Trial
Circulation 2022cited by 141position: middledoi
Renal effects of empagliflozin in patients hospitalized for acute heart failure: from the <scp>EMPULSE</scp> trial
European Journal of Heart Failure 2022cited by 78position: middledoi
Sodium–glucose co‐transporter 2 inhibition in patients hospitalized for acute decompensated heart failure: rationale for and design of the <scp>EMPULSE</scp> trial
European Journal of Heart Failure 2021cited by 103position: middledoi
Design and Rationale of the <scp>RE‐DUAL PCI</scp> Trial: A Prospective, Randomized, Phase 3b Study Comparing the Safety and Efficacy of Dual Antithrombotic Therapy With Dabigatran Etexilate Versus Warfarin Triple Therapy in Patients With Nonvalvular Atrial Fibrillation Who Have Undergone Percutaneous Coronary Intervention With Stenting
Clinical Cardiology 2016cited by 71position: middledoi
Dabigatran versus Warfarin in Patients with Mechanical Heart Valves
New England Journal of Medicine 2013cited by 1,493position: middledoi
Telmisartan on Top of Antihypertensive Treatment Does Not Prevent Progression of Cerebral White Matter Lesions in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) MRI Substudy
Stroke 2012cited by 83position: middledoi
Risk of Recurrent Stroke in Patients With Silent Brain Infarction in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) Imaging Substudy
Stroke 2012cited by 22position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Martina Brueckmann · University Hospital Heidelberg7 papers (2013–2024)Michael E. Nassif · Baim Institute for Clinical Research6 papers (2021–2024)João Pedro Ferreira · Institut des Sciences et technologies pour une Economie Circulaire des énergies bas carbone6 papers (2021–2024)John R. Teerlink · University of Glasgow6 papers (2021–2024)Piotr Ponikowski · University of Business in Wrocław6 papers (2021–2024)Mitchell A. Psotka · Inova Fairfax Hospital6 papers (2021–2024)Mikhail Kosiborod · Nagoya University6 papers (2021–2024)Sean P. Collins · Rutgers Cancer Institute6 papers (2021–2024)Jasper Tromp · National University of Singapore6 papers (2021–2024)Christiane E. Angermann · Universitätsklinikum Würzburg6 papers (2021–2024)Adriaan A. Voors · Centre Hospitalier Régional et Universitaire de Nancy6 papers (2021–2024)Jan Biegus · University of Wrocław6 papers (2021–2024)Afshin Salsali · Universitätsklinikum Würzburg4 papers (2021–2022)Ralph L. Sacco · Lotus Clinical Research2 papers (2012–2012)Elke R. Gizewski · VASP Software (Austria)2 papers (2012–2012)Ralph Weber · United Nations Economic and Social Commission for Asia and the Pacific2 papers (2012–2012)Andrew M. Demchuk · Victoria General Hospital2 papers (2012–2012)Christian Weimar · Institut für Medizinische Informatik, Biometrie und Epidemiologie2 papers (2012–2012)Anke Diehl · University of Duisburg-Essen2 papers (2012–2012)Karin Hermansson · Boehringer Ingelheim (Sweden)2 papers (2012–2012)